Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · National Healthcare (NHC)

National HealthCare Adds Two Directors, Expanding Board to Nine Members

Neutral Impact 2 of 5 leadership Written later

National HealthCare Corporation increased its board from seven to nine directors effective February 12, 2026, appointing Dr. David Gifford and Andrew Adams to fill the new seats. The filing is a governance change with no reported financial results, and it adds a geriatric health policy background and long-term care administration experience to the board.

Key points

  • Board expanded by two seats to nine directors effective February 12, 2026
  • Dr. David Gifford, a geriatrician and former AHCA/NCAL official, named a Class 2 director and Nominating and Corporate Governance Committee member
  • Andrew Adams, a long-term care administrator and grandson of founder Dr. Carl Adams, named a Class 1 director with a 2026 shareholder vote and Compensation Committee role

The filing

CompanyNational Healthcare (NHC)
Form8-K, current report
Filed with the SECFeb 17, 2026, 10:38 AM ET
Accession number0001437749-26-004270

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:39 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 17, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.